Genetic Determinants of Clindamycin/Rifampin Interaction
NCT ID: NCT03267225
Last Updated: 2022-10-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
84 participants
OBSERVATIONAL
2016-01-31
2021-04-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Secondary objectives To study the influence of these polymorphisms on clindamycin clearance, before combination therapy with rifampin (clindamycin monotherapy) To study the influence of these polymorphisms on CYP450 activity before combination therapy with rifampin (clindamycin monotherapy) To study the influence of these polymorphisms on the increase of CYP450 activity after clindamycin/rifampin combination therapy To study the difference between the expected and observed clindamycin serum concentrations after dosage adjustment, in patients with clindamycin dosage adjustment after combination therapy with rifampin
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clindamycin-rifampin Drug Interaction in the Treatment of Bone and Joint Infections
NCT02629770
Pharmacological Interaction of Rifampicin on Clindamycin in Staphylococcic Osteoarticular Infections
NCT02782078
Population Pharmacokinetics of Commonly Used Antimicrobial Agents in Children of Bacterial Meningitis With Augmented Renal Clearance
NCT04771884
Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections
NCT04785924
Flucloxacillin as an Inducer of CYP-enzymes
NCT04840641
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* After at least 24 hours of clindamycin therapy and before combination therapy with rifampin:
* 1 urine sample (5 mL) for CYP 450 activity phenotyping
* 1 blood sample (5 mL on ethylenediaminetetraacetic acid (EDTA) tubes) for measuring clindamycin serum concentration and genotyping
* After ten days of clindamycin-rifampin combination therapy:
* 1 urine sample (5 mL) for CYP 450 activity phenotyping
* 1 blood sample (5 mL on EDTA tubes) for measuring clindamycin serum concentration and genotyping
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* aged ≥ 18 years old
* treatment with clindamycin/rifampin combination therapy \> 10 days
Exclusion Criteria
* pregnant or breast feeding patient
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondation Ophtalmologique Adolphe de Rothschild
NETWORK
Dr Valerie ZELLER
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Valerie ZELLER
MD, principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Valérie Zeller, MD
Role: PRINCIPAL_INVESTIGATOR
GH Diaconesses Croix Saint Simon
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Groupe Hospitalier Diaconesses Croix Saint Simon
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D-VZR_2015_3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.